Company intelligence / Profile preview
iOnctura
Amsterdam, Netherlandsionctura.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 2
01
Overview
iOnctura has advanced two therapeutic candidates into mid-stage clinical development. Roginolisib is the first allosteric modulator of PI3Kδ with promising efficacy and safety profile. Cambritaxestat is the only autotaxin inhibitor currently in cancer clinical development. Early results suggest potential to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on iOnctura.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iOnctura.